Literature DB >> 2536628

Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats.

C E Van der Zee1, R G Van der Hoop, W H Gispen.   

Abstract

An injection of streptozocin (STZ) was used to study diabetes-induced peripheral neuropathy in rats. In such rats the values of motor nerve conduction velocity and sensory nerve conduction velocity were decreased compared with the values obtained in nondiabetic controls from 3 wk after STZ injection onward. In recent years it has been extensively documented that peptides related to ACTH and MSH exert a neurotrophic effect on the nervous system that results in enhanced recovery of function after mechanical nerve damage. This article documents the beneficial effect of the peptide Org 2766, an ACTH-(4-9) analogue, in diabetic peripheral neuropathy. Chronic subcutaneous treatment of diabetic rats with Org 2766 results in a significant enhancement of both motor and sensory nerve conduction velocity compared with saline-treated diabetic rats. Histological analysis of cross sections of the sural nerve showed no difference in the total number of nerve fibers in saline- or peptide-treated diabetic rats. In contrast, a difference in fiber size distribution was demonstrated; i.e., the sural nerves of diabetic rats contained fewer thick myelinated fibers. Treatment with Org 2766 resulted in a normal distribution. Apparently, the peptide Org 2766 has a protective action on nerve fibers and nerve function during STZ-induced diabetes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536628     DOI: 10.2337/diab.38.2.225

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.

Authors:  G D Valk; A C Kappelle; A M Tjon-A-Tsien; B Bravenboer; K Bakker; R P Michels; C M Groenhout; F W Bertelsmann
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

2.  Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.

Authors:  B Bravenboer; P H Hendrikse; P L Oey; A C van Huffelen; C Groenhout; W H Gispen; D W Erkelens
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

3.  Amelioration by the Ca2+ antagonist, nimodipine of an existing neuropathy in the streptozotocin-induced, diabetic rat.

Authors:  A C Kappelle; B Bravenboer; T van Buren; J Traber; D W Erkelens; W H Gispen
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

4.  ACTH4-9 analogue ORG 2766 can improve existing neuropathy in streptozocin-induced diabetic rats.

Authors:  B Bravenboer; A C Kappelle; T van Buren; D W Erkelens; W H Gispen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

5.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

6.  Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat.

Authors:  B Bravenboer; A C Kappelle; F P Hamers; T van Buren; D W Erkelens; W H Gispen
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.